Tae Hyung Han

Rovalpituzumab tesirine, a DLL3-targeted antibody-drug conjugate, in recurrent small-cell lung cancer: a first-in-human, first-in-class, open-label, phase 1 study

Charles M. Rudin, M. Catherine Pietanza, Todd M. Bauer et al. · The Lancet Oncology · 2016 · 537 citations · Full text

Dll3-targeted Antibody-drug Conjugate, Medicine, Immunology +6

A Phase I Weekly Dosing Study of Brentuximab Vedotin in Patients with Relapsed/Refractory CD30-Positive Hematologic Malignancies

Michelle A. Fanale, Andres Forero‐Torres, Joseph D. Rosenblatt et al. · Clinical Cancer Research · 2011 · 213 citations · Full text

Tolerability of Fosaprepitant and Bioequivalency to Aprepitant in Healthy Subjects

Kenneth C. Lasseter, Jay J. Gambale, Bo Jin et al. · The Journal of Clinical Pharmacology · 2007 · 132 citations

Drug Safety, Oral Nk1 Antagonist, Oncology +12

CYP3A-Mediated Drug-Drug Interaction Potential and Excretion of Brentuximab Vedotin, an Antibody−Drug Conjugate, in Patients With CD30-Positive Hematologic Malignancies

Tae Hyung Han, Ajay K. Gopal, Radhakrishnan Ramchandren et al. · The Journal of Clinical Pharmacology · 2013 · 99 citations · Full text

Potent and Selective Agonism of the Melanocortin Receptor 4 With MK-0493 Does Not Induce Weight Loss in Obese Human Subjects: Energy Intake Predicts Lack of Weight Loss Efficacy

Rajesh Krishna, Barry Gumbiner, C. Melinda Stevens et al. · Clinical Pharmacology & Therapeutics · 2009 · 83 citations